REDD1 is a determinant of low-dose metronomic doxorubicin-elicited endothelial cell dysfunction through downregulation of VEGFR-2/3 expression

Minsik Park, Young‐Myeong Kim|Experimental & Molecular Medicine|2021

Cited by 16